Information Provided By: 
Fly News Breaks for February 20, 2019
TEVA
Feb 20, 2019 | 04:48 EDT
Mizuho analyst Irina Koffler downgraded Teva Pharmaceutical to Neutral and lowered her price target for the shares to $18 from $25. The analyst says her investment thesis is "broken" after Teva's "disappointing 2019 guidance and cautious longer-term outlook." The company's cost-cutting and deleveraging will take longer than expected, Koffler tells investors in a research note. Without any key data readouts this year, Koffler sees few growth catalysts for Teva in 2019.
News For TEVA From the Last 2 Days
There are no results for your query TEVA
